- Product Description Description
- Table of Contents TOC
- List of Table & Figure LOT
- Get Free Sample PDF Sample PDF
Market Size, 2025
$8.40 BnMarket Estimate, 2026
$9.24 BnMarket Forecast, 2034
$19.82 BnCAGR, 2026–2034
10.01%U.S. Molecular Diagnostics Market Size, Growth, Trends & Forecast (2026–2034)
The U.S. molecular diagnostics market size was valued at USD 8.40 billion in 2025, reached USD 9.24 billion in 2026, and is projected to reach USD 19.82 billion by 2034, growing at a compound annual growth rate (CAGR) of 10.01% from 2026 to 2034. Driven by the rising adoption of MDx for infectious diseases, an expanding aging demographic prone to chronic illnesses, and ongoing technological breakthroughs in personalized medicine and portable diagnostic platforms, the market demonstrates powerful long-term growth.
Key Executive Metrics (At-a-Glance)
- 2025 Base Valuation: USD 8.40 Billion
- 2026 Current Valuation: USD 9.24 Billion
- 2034 Forecast Valuation: USD 19.82 Billion
- Compound Annual Growth Rate (CAGR): 10.01% (2026–2034)
- Regional Standing: United States (Holds the dominant revenue share within the North American molecular diagnostics ecosystem)
Core Market Drivers & Growth Triggers
- Infectious Disease Testing: High utilization rates for detecting influenza, hepatitis, HPV, HIV, and tuberculosis.
- Aging Population & Chronic Illnesses: Increasing life expectancy driving up the prevalence of cancer, diabetes, and cardiovascular conditions.
- Precision Medicine & Advanced Tech: Broad acceptance of personalized therapies, cost-effective assays, and portable screening instruments.
Primary Market Restraints & Challenges
- Approval Delays & Regulations: Lengthy regulatory greenlights for novel tests and strict compliance frameworks for new techniques.
- Reimbursement Barriers & High Costs: Poor reimbursement policies (such as for GAS nucleic acid tests) coupled with expensive diagnostic procedures in oncology and neurology.
- Operational Hurdles: Rapid microbial mutations and a shortage of skilled laboratory professionals.
U.S. Molecular Diagnostics Market Segmentation Breakdown
| Segment Category | Key Segment Classifications |
|---|---|
| By Products and Service | Reagents and kits, Instruments, and Software and service |
| By Technology | Polymerase Chain Reaction (PCR), Isothermal Nucleic Acid Amplification Technology (INAAT), DNA Sequencing and NGS, DNA Microarrays, In Situ Hybridization, and Other Technologies |
| By End-User | Hospital and Academic Laboratories, Reference Laboratories, and Other End-Users |
| By Country | United States |
Major Industry Players Profiled
Key corporations shaping the U.S. molecular diagnostics market include Abbott Laboratories, Agilent Technologies, Becton, Dickinson And Company, Biomérieux SA, Danaher Corporation, Diasorin, Grifols, Hologic, Illumina, Qiagen, Roche Diagnostics, Siemens Healthineers, and Thermo Fisher Scientific.
U.S. Molecular Diagnostics Market Size
The U.S. molecular diagnostics market was valued at USD 8.40 billion in 2025, is estimated to reach USD 9.24 billion in 2026, and is projected to reach USD 19.82 billion by 2034, growing at a CAGR of 10.01% from 2026 to 2034.
The growing adoption of Molecular Diagnostics (MDx) for infectious diseases like influenza, hepatitis, HPV, HIV, and tuberculosis drives the U.S. Molecular Diagnostics Market during the forecast period. In addition, the growth in the aged population year by year is boosting the market. For instance, according to World Health Organisation, the average person's life expectancy was increased to 80 years, due to which the senior population is increasing. As aged people are apt to get a chronic illnesses, the United States witnessed a gradual increase in chronic diseases like diabetes, cancer, cardiovascular diseases, etc.
Moreover, a rising number of new solutions for cancer diagnostics and the increasing acceptance and awareness of personalized medicines among people are boosting the market. As a result, the diagnosis had become much cheaper and more accurate due to advancements in molecular techniques fueling the United States Molecular Diagnostics Market. In addition, the increase in demand for portable devices is encouraging the growth of the U.S. Molecular Diagnostics Market.
The new molecular diagnostic tests' approval is delayed, a major restrain for the U.S. Molecular Diagnostics Market. Furthermore, due to poor reimbursement policies, the United States molecular diagnostic market for group A streptococcus (GAS) nucleic acid (N.A.) tests is being obstructed. In addition, the stringent regulatory requirements for new molecular diagnostic techniques and the rapid mutation of microbes hinder the growth of the U.S. Molecular Diagnostics Market. Moreover, the rising costs for the diagnostics of diseases like oncology and neurology are estimated to hinder the U.S. Molecular Diagnostics Market growth during the forecast period. Further, the lack of skilled professionals in the united states is limiting the extension of the market.
MARKET SEGMENTATION
This research report on the U.S. molecular diagnostics market has been segmented and sub-segmented into the following categories.
By Products and Service
- Reagents and kits
- Instruments
- Software and service
By Technology
- Polymerase Chain Reaction (PCR)
- Isothermal Nucleic Acid Amplification Technology (INAAT)3.
- DNA Sequencing and NGS
- DNA Microarrays
- In Situ Hybridization
- Other Technologies
By End-User
- Hospital and Academic Laboratories
- Reference Laboratories
- Other End-Users
By Country
- United States
Geographically, the United States held the largest revenue share in 2019 and is expected to be the major contributor to the North American Molecular Diagnostics Market during the forecast period. As a result, the United States Molecular Diagnostics Market is estimated to have tremendous growth during the forecast period. The increasing partnerships between pharmaceutical companies to develop safe diagnostics drive the U.S. molecular diagnostics market. In addition, the rising number of infectious diseases and cancer cases boosts the market growth. For instance, according to the American Cancer Society, more than 1,76,000 were affected by cancer in the United States, and approximately 606,000 people died in 2019.
Moreover, the new regulatory strategies for NGS tests by FDA propel the U.S. Molecular Diagnostics Market. Also, the rising geriatric population, increasing technological advancements, and the U.S. government's initiatives, like increasing investments and funds, are boosting the market growth. Also, the presence of many market players in this region is fueling the growth of the U.S. Molecular Diagnostics Market.
KEY MARKET PARTICIPANTS
Companies such as Abbott Laboratories, Agilent Technologies, Becton, Dickinson And Company, Biomérieux SA, Danaher Corporation, Diasorin, Grifols, Hologic, Illumina, Qiagen, Roche Diagnostics, Siemens Healthineers, Thermo Fisher Scientific are some of the notable companies operating in the U.S. molecular diagnostics market.